Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | DHFR | P00374 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3692533 | 0.79 | ADORA2A (0.57) | ADORA2APIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL3537607 | 0.78 | ADORA2A (0.55) | ADORA2APIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL30965441 | 0.76 | ADORA2A (0.53) | ADORA2APIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL63822 | 0.76 | ADORA2A (0.53) | ADORA2APIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL14268538 | 0.76 | ADORA2A (0.48) | ADORA2APIK3CGPIK3CAPIK3CBHDAC6 | |
| Bromide SCHEMBL11633687 | 0.74 | ADORA2A (0.52) | ADORA2APIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL14435374 | 0.73 | NOS1 (0.55) | DHFRNOS1 | |
| SCHEMBL30432658 | 0.73 | NOS1 (0.55) | DHFRNOS1 | |
| SCHEMBL64019 | 0.72 | NOS1 (0.54) | PIK3CGDHFRNOS1CA1CA2 | |
| SCHEMBL11631985 | 0.72 | ADORA2A (0.48) | ADORA2APIK3CGPIK3CAPIK3CBHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305134-A1 | SPECIFIC INHIBITORS OF PTERIDINE REDUCTASE WITH ANTIPARASITIC ACTION | TYDOCK PHARMA S.R.L. (IT) | 2010-12-02 | — | — | US | claimed |
| EP-2234998-A2 | SPECIFIC INHIBITORS OF PTERIDINE REDUCTASE WITH ANTIPARASITIC ACTION | Tydock Pharma S.r.l. (IT) | 2010-10-06 | — | — | EP | claimed |
| WO-2009080367-A2 | SPECIFIC INHIBITORS OF PTERIDINE REDUCTASE WITH ANTIPARASITIC ACTION | TYDOCKPHARMA S.R.L. (IT) | 2009-07-02 | — | — | WO | claimed |
| EP-3893939-A1 | NANOPARTICLE-BASED THERAPY OF INFLAMMATORY DISORDERS | Midatech Ltd (GB) | 2021-10-20 | — | — | EP | disclosed |
| WO-2020120787-A1 | NANOPARTICLE-BASED THERAPY OF INFLAMMATORY DISORDERS | MIDATECH LTD (GB) | 2020-06-18 | — | — | WO | disclosed |
| EP-2234998-B1 | SPECIFIC INHIBITORS OF PTERIDINE REDUCTASE WITH ANTIPARASITIC ACTION | TYDOCK PHARMA S R L (IT) | 2015-08-19 | — | — | EP | disclosed |
| US-20100305134-A1 | SPECIFIC INHIBITORS OF PTERIDINE REDUCTASE WITH ANTIPARASITIC ACTION | TYDOCK PHARMA S.R.L. (IT) | 2010-12-02 | — | — | US | disclosed |
| EP-2234998-A2 | SPECIFIC INHIBITORS OF PTERIDINE REDUCTASE WITH ANTIPARASITIC ACTION | Tydock Pharma S.r.l. (IT) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009080367-A2 | SPECIFIC INHIBITORS OF PTERIDINE REDUCTASE WITH ANTIPARASITIC ACTION | TYDOCKPHARMA S.R.L. (IT) | 2009-07-02 | — | — | WO | disclosed |
| US-4079056-A | REACTING 2,4-DIAMINO-6-PTERIDINE-METHANOL-HBR WITH TRIPHENYLPHOSPHINE DIBROMIDE OR PHOSPHORUS TRIBROMIDE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1978-03-14 | — | — | US | disclosed |
| US-4077957-A | INTERMEDIATE FOR METHOTREXATE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1978-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305134-A1 | SPECIFIC INHIBITORS OF PTERIDINE REDUCTASE WITH ANTIPARASITIC ACTION | QDPR, DHFR, DDC | ADORA2A 1687/4885PIK3CG 3307/4885PIK3CA 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.